Aims To review systematically the published literature on extended‐release naltrexone (XR‐
NTX, Vivitrol®), marketed as a once‐per‐month injection product to treat opioid use …

This paper is the fortieth consecutive installment of the annual anthological review of
research concerning the endogenous opioid system, summarizing articles published during …

The United States is in the middle of a historically unprecedented opioid epidemic. Today,
more people die of drug overdoses than any other form of accidental death, and opioid …

Background and aim This is a follow‐up study of a previously published randomized clinical
trial conducted in Norway that compared extended‐release naltrexone (XR‐NTX) to …

Pharmacotherapy for opioid addiction with methadone, buprenorphine, and naltrexone has
proven efficacy in reducing illicit opioid use. These treatments are under-utilized among …

Background Long acting intramuscular (IM) naltrexone is an effective treatment for opioid
use disorder (OUD), but rates and correlates of its use have not been studied. Methods …

Vivitrol is an extended-release injectable formulation of naltrexone, administered as an
intramuscular injection once a month. Naltrexone is an opioid-receptor antagonist that …

Background: Prior systematic reviews have compared the relative effectiveness of
buprenorphine (BUP), methadone (MET) and other medications and treatments for opioid …

Background and aims Extended-release naltrexone (XR-NTX) is an under-used treatment
option for opioid dependence, today only available in a few countries in the world. Although …

Background and aim Extended-release naltrexone (XR-NTX) blocks the effects of opioids for
4 weeks; however, starting treatment can be challenging because it requires 7 to 10 days of …